|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|
| Revenue | ||
| Cost of sales | ||
| Gross profit | ||
| Research and development expenses | ||
| Selling, general and administrative expenses | ||
| Restructuring and acquisition costs | ||
| Share based payment expense | ||
| Impairment charge | ||
| Operating loss before finance expense | ||
| Non-cash change in fair value of contingent consideration | ||
| Non-cash contingent value rights gain / (loss) | ||
| Net finance expense - other | ||
| Loss on ordinary activities before taxation | ||
| Tax credit on loss on ordinary activities | ||
| Profit/loss for the year attributable to the equity holders of the Company | ||
| Exchange translation differences which may be reclassified through profit or loss | ||
| Total other comprehensive income/(loss) | ||
| Total comprehensive income/(loss) for the year attributable to the equity holders of the Company | ||
| Loss per share - basic and diluted, attributable to ordinary equity holders of the parent (US$) (in dollars per share) | ||
| Earnings/(loss) per share | ||
| Basic earnings/(loss) per share attributable to ordinary equity holders of the parent (in dollars per share) | ||
| Diluted earnings/(loss) per share attributable to ordinary equity holders of the parent (in dollars per share) |
Loading...
